表紙
市場調查報告書

痛風性關節炎 (痛風) :開發中產品分析

Gouty Arthritis (Gout) - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 232848
出版日期 內容資訊 英文 125 Pages
訂單完成後即時交付
價格
痛風性關節炎 (痛風) :開發中產品分析 Gouty Arthritis (Gout) - Pipeline Review, H1 2020
出版日期: 2020年05月30日內容資訊: 英文 125 Pages
簡介

痛風是關節炎的一種,會讓血液中積存尿酸,並在關節發炎的疾病。主要症狀有發病部分的關節腫脹,其週邊皮膚發熱並僵硬化,還會發紅並帶光澤,會突然感到激痛,關節脆弱等。致病因子有肥胖及酗酒、關節部分外傷、長期腎臟疾病、攝取過多含有普林的食物等。主要治療方法有非甾體抗炎藥物(NSAID)等。

本報告提供全球各國治療痛風性關節炎 (痛風) 所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

痛風性關節炎 (痛風)的概要

治療藥的開發

  • 開發中產品的概要
  • 各企業的開發平台
  • 大學/研究機關所開發的開發平台
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

痛風性關節炎 (痛風)的治療藥開發企業

  • Allena Pharmaceuticals Inc
  • AstraZeneca Plc
  • C&C Research Laboratories
  • Cell Medica Ltd
  • CymaBay Therapeutics Inc
  • Genentech Inc
  • Immune Response BioPharma Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • Monosol Rx LLC
  • Opsona Therapeutics Ltd
  • Polaris Pharmaceuticals Inc
  • Rigel Pharmaceuticals Inc
  • Swedish Orphan Biovitrum AB
  • TEIJIN FIBERS製藥
  • Wellstat Therapeutics Corp
  • XL-protein GmbH

藥物簡介

痛風性關節炎 (痛風) :暫停中的計劃

痛風性關節炎 (痛風) :開發中止的產品

痛風性關節炎 (痛風) :產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC12246IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gouty Arthritis - Pipeline Review, H1 2020, provides an overview of the Gouty Arthritis (Musculoskeletal Disorders) pipeline landscape.

Gout is a type of arthritis where swelling and severe pain develops in joints, especially at the base of the big toe. Gout occurs when uric acid builds up in blood and causes inflammation in the joints. Symptoms include sudden onset of joint pain, joint swelling, heat in the affected area and joint redness. Risk factors include obesity, high alcohol intake, injury to a joint, long-standing kidney disease and high intake of foods rich in purines.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gouty Arthritis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Gouty Arthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gouty Arthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Gouty Arthritis (Gout) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 2, 15, 6, 1, 20 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Gouty Arthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gouty Arthritis (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Gouty Arthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gouty Arthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gouty Arthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gouty Arthritis (Musculoskeletal Disorders)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gouty Arthritis (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gouty Arthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Gouty Arthritis (Gout) - Overview
  • Gouty Arthritis (Gout) - Therapeutics Development
  • Gouty Arthritis (Gout) - Therapeutics Assessment
  • Gouty Arthritis (Gout) - Companies Involved in Therapeutics Development
  • Gouty Arthritis (Gout) - Drug Profiles
  • Gouty Arthritis (Gout) - Dormant Projects
  • Gouty Arthritis (Gout) - Discontinued Products
  • Gouty Arthritis (Gout) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Gouty Arthritis (Gout), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Gouty Arthritis (Gout) - Pipeline by Acquist Therapeutics, H1 2020
  • Gouty Arthritis (Gout) - Pipeline by Aequus BioPharma Inc, H1 2020
  • Gouty Arthritis (Gout) - Pipeline by Arthrosi Therapeutics Inc, H1 2020
  • Gouty Arthritis (Gout) - Pipeline by C&C Research Laboratories, H1 2020
  • Gouty Arthritis (Gout) - Dormant Projects, H1 2020
  • Gouty Arthritis (Gout) - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Gouty Arthritis (Gout) - Dormant Projects, H1 2020 (Contd..2), H1 2020
  • Gouty Arthritis (Gout) - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Gouty Arthritis (Gout), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020